Vadim Baykov

666 total citations
47 papers, 480 citations indexed

About

Vadim Baykov is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Vadim Baykov has authored 47 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 18 papers in Genetics. Recurrent topics in Vadim Baykov's work include Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Vadim Baykov is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Vadim Baykov collaborates with scholars based in Russia, Norway and United States. Vadim Baykov's co-authors include Anders Sundan, Magne Børset, Anders Waage, Randi Utne Holt, Torstein B. Rø, Carina Seidel, Henrik Hjorth‐Hansen, Unn‐Merete Fagerli, Ivan Moiseev and Kirill V. Lepik and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Vadim Baykov

32 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vadim Baykov Russia 11 207 198 163 118 70 47 480
Sophie Derenne France 8 362 1.7× 338 1.7× 418 2.6× 88 0.7× 29 0.4× 11 780
Florian Ewald Germany 16 228 1.1× 37 0.2× 492 3.0× 107 0.9× 42 0.6× 25 792
Esther J.M. Schilder-Tol Netherlands 11 146 0.7× 33 0.2× 177 1.1× 221 1.9× 99 1.4× 14 612
Regine Leo Germany 9 326 1.6× 478 2.4× 430 2.6× 69 0.6× 41 0.6× 12 776
Shuji Arita Japan 15 302 1.5× 25 0.1× 218 1.3× 46 0.4× 37 0.5× 44 558
Andrei Cucuianu Romania 11 82 0.4× 114 0.6× 284 1.7× 39 0.3× 10 0.1× 32 509
Gerrit‐Jan Schuurhuis Netherlands 12 151 0.7× 488 2.5× 267 1.6× 41 0.3× 12 0.2× 23 693
Julie Madden United Kingdom 9 212 1.0× 33 0.2× 214 1.3× 36 0.3× 33 0.5× 14 502
María Laura Gutiérrez Spain 15 195 0.9× 54 0.3× 145 0.9× 182 1.5× 12 0.2× 30 496

Countries citing papers authored by Vadim Baykov

Since Specialization
Citations

This map shows the geographic impact of Vadim Baykov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vadim Baykov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vadim Baykov more than expected).

Fields of papers citing papers by Vadim Baykov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vadim Baykov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vadim Baykov. The network helps show where Vadim Baykov may publish in the future.

Co-authorship network of co-authors of Vadim Baykov

This figure shows the co-authorship network connecting the top 25 collaborators of Vadim Baykov. A scholar is included among the top collaborators of Vadim Baykov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vadim Baykov. Vadim Baykov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
Kozlov, Andrey V., et al.. (2023). CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and fever. 12(1). 41–45. 1 indexed citations
6.
7.
Lepik, Kirill V., Marina Popova, Vadim Baykov, et al.. (2021). Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma. International Journal of Clinical Oncology. 27(3). 626–632. 10 indexed citations
8.
Lepik, Kirill V., Elena Kondakova, Vadim Baykov, et al.. (2021). Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma. Annals of Hematology. 100(3). 691–698. 12 indexed citations
9.
Popova, Marina, et al.. (2020). 892MO High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma. Annals of Oncology. 31. S651–S651. 1 indexed citations
10.
Morozova, Elena, Ivan Moiseev, Moiseev Si, et al.. (2020). A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. Acta Haematologica. 144(2). 158–165. 27 indexed citations
11.
Morozova, Еlena V., Ivan Moiseev, Vadim Baykov, et al.. (2020). Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome. Leukemia Research Reports. 14. 100215–100215. 12 indexed citations
12.
Kozlov, Andrey V., Kirill V. Lepik, Elena Kondakova, et al.. (2020). Treatment options for T-cell lymphomas: a single-center study. 9(1). 28–37. 1 indexed citations
13.
Baykov, Vadim, et al.. (2019). Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Hematology/Oncology and Stem Cell Therapy. 12(3). 140–145. 9 indexed citations
14.
Kozlov, Andrey V., Kirill V. Lepik, Vadim Baykov, et al.. (2019). Nivolumab in pediatric Hodgkin's lymphoma. 8(4). 41–48. 8 indexed citations
15.
Lepik, Kirill V., Elena Kondakova, Vadim Baykov, et al.. (2018). Interim analysis of effectiveness and safety of Nivolumab 40 mg in relapsed/refractory Hodgkin lymphoma. 7(3). 1 indexed citations
16.
17.
Morozova, Еlena V., Ivan Moiseev, Sergey N. Bondarenko, et al.. (2017). Graft-Versus-Host Disease Prophylaxis with Posttransplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. Blood. 130. 4492–4492. 2 indexed citations
18.
Lepik, Kirill V., Elena Kondakova, Andrey V. Kozlov, et al.. (2017). Regaining the Tumor Control in Relapsed/Refractory Hodgkin Lymphoma after Nivolumab Failure with Addition of Another Antineoplastic Agent. Blood. 130. 1521–1521. 2 indexed citations
19.
Holt, Randi Utne, Unn‐Merete Fagerli, Vadim Baykov, et al.. (2008). Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica. 93(4). 619–622. 35 indexed citations
20.
Standal, Therese, Henrik Hjorth‐Hansen, Thomas Rasmussen, et al.. (2004). Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.. PubMed. 89(2). 174–82. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophie Derenne Breakdown of academic impact, for papers by Florian Ewald Breakdown of academic impact, for papers by Esther J.M. Schilder-Tol Breakdown of academic impact, for papers by Regine Leo Breakdown of academic impact, for papers by Shuji Arita Breakdown of academic impact, for papers by Andrei Cucuianu Breakdown of academic impact, for papers by Gerrit‐Jan Schuurhuis Breakdown of academic impact, for papers by Julie Madden Breakdown of academic impact, for papers by María Laura Gutiérrez
Rankless by CCL
2026